Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GT Biopharma ( (GTBP) ) just unveiled an announcement.
In September 2025, GT Biopharma, Inc. announced that holders of its Series L 10% Convertible Preferred Stock agreed to waive their redemption rights as outlined in the Certificate of Designations. This waiver could potentially impact the company’s financial flexibility and investor relations by altering the terms under which these securities operate.
The most recent analyst rating on (GTBP) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.
Spark’s Take on GTBP Stock
According to Spark, TipRanks’ AI Analyst, GTBP is a Underperform.
GT Biopharma’s overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.
To see Spark’s full report on GTBP stock, click here.
More about GT Biopharma
Average Trading Volume: 215,715
Technical Sentiment Signal: Sell
Current Market Cap: $2.85M
For an in-depth examination of GTBP stock, go to TipRanks’ Overview page.